, /PRNewswire/ -- ToxStrategies, a best-in-class, multidisciplinary scientific consulting firm, today announced the acquisition of Clintrex Research Corporation. Founded in 2008 by Dr. C.
, Dr. , and , Clintrex operationalizes clinical and regulatory development pathways for new treatments for neurodegenerative and other central nervous system diseases. ToxStrategies is a portfolio company of Renovus Capital Partners.
Terms of the transaction were not disclosed. ToxStrategies partnered with Renovus Capital Partners in with the goal of expanding its existing client base and developing new end markets. The acquisition of Clintrex by ToxStrategies brings together two best-in-class firms within the life sciences industry, with a unified focus on providing integrated teams to solve the multifaceted problems and challenges faced by our clients, particularly in the drug development space.
Drs. Olanow and Kieburtz will continue to lead Clintrex as a Division of ToxStrategies. Clintrex staff includes world-renowned experts in various aspects of drug development who collaborate with clients to identify and solve pre-clinical science, clinical trial, biostatistical and regulatory issues that are critical to product development and approval.
This internationally recognized team of experts has developed a unique and proven approach for conducting clinical trials that serves to minimize variability, facilitate recruitment, require smaller sample sizes, and increase the likelihood of accura.